Chen H
Liver Res. 2025; 6(4):203-213.
PMID: 39957910
PMC: 11791839.
DOI: 10.1016/j.livres.2022.09.003.
Zhang S, Zhao W, Sun L, Liang G, Wang X, Zeng H
BMC Med Imaging. 2025; 25(1):31.
PMID: 39885407
PMC: 11783902.
DOI: 10.1186/s12880-025-01567-7.
Lu S, Liu Z, Qi M, Wang Y, Chang L, Bai X
Front Cell Dev Biol. 2025; 12:1510390.
PMID: 39744014
PMC: 11688369.
DOI: 10.3389/fcell.2024.1510390.
Meloni A, Pistoia L, Ricchi P, Longo F, Cecinati V, Sorrentino F
J Clin Med. 2024; 13(16).
PMID: 39200932
PMC: 11355279.
DOI: 10.3390/jcm13164791.
Meloni A, Pistoia L, Spasiano A, Cossu A, Casini T, Massa A
Antioxidants (Basel). 2024; 13(4).
PMID: 38671894
PMC: 11047726.
DOI: 10.3390/antiox13040446.
Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia.
Bardon-Cancho E, Marco-Sanchez J, Beneitez-Pastor D, Payan-Pernia S, Llobet A, Berrueco R
Ann Hematol. 2024; 103(5):1525-1539.
PMID: 38519604
PMC: 11009731.
DOI: 10.1007/s00277-024-05694-z.
Ferroptosis and metabolic syndrome and complications: association, mechanism, and translational applications.
Zhou D, Lu P, Mo X, Yang B, Chen T, Yao Y
Front Endocrinol (Lausanne). 2024; 14:1248934.
PMID: 38260171
PMC: 10800994.
DOI: 10.3389/fendo.2023.1248934.
Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.
Darvishi-Khezri H, Karami H, Naderisorki M, Ghazaiean M, Kosaryan M, Mosanejad-Galchali A
PLoS One. 2024; 19(1):e0284267.
PMID: 38215162
PMC: 10786396.
DOI: 10.1371/journal.pone.0284267.
[Latest Findings on Ferroptosis and Osteoarthropathy].
An K, Zhou X
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024; 54(6):1294-1299.
PMID: 38162082
PMC: 10752773.
DOI: 10.12182/20231160209.
Low Vitamin D Levels Are Associated with Increased Cardiac Iron Uptake in Beta-Thalassemia Major.
Meloni A, Pistoia L, Vassalle C, Spasiano A, Fotzi I, Bagnato S
Diagnostics (Basel). 2023; 13(24).
PMID: 38132240
PMC: 10742632.
DOI: 10.3390/diagnostics13243656.
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.
Kontoghiorghes G
Int J Mol Sci. 2023; 24(23).
PMID: 38069073
PMC: 10706143.
DOI: 10.3390/ijms242316749.
Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict.
Touma H, Youssef L, Al-Salhi L, Ismail Al-Khalil W, AlKeba K
Biomed Res Int. 2023; 2023:8911518.
PMID: 37743972
PMC: 10513871.
DOI: 10.1155/2023/8911518.
Multi-Parametric Cardiac Magnetic Resonance for Prediction of Heart Failure Death in Thalassemia Major.
Meloni A, Pistoia L, Gamberini M, Cuccia L, Lisi R, Cecinati V
Diagnostics (Basel). 2023; 13(5).
PMID: 36900034
PMC: 10001258.
DOI: 10.3390/diagnostics13050890.
The Impacts of Iron Overload and Ferroptosis on Intestinal Mucosal Homeostasis and Inflammation.
Huo C, Li G, Hu Y, Sun H
Int J Mol Sci. 2022; 23(22).
PMID: 36430673
PMC: 9697168.
DOI: 10.3390/ijms232214195.
Ferroptosis: A potential target for the intervention of intervertebral disc degeneration.
Zhou L, Zhang R, Jia C, Kang L, Zhang Z, Zhang H
Front Endocrinol (Lausanne). 2022; 13:1042060.
PMID: 36339421
PMC: 9630850.
DOI: 10.3389/fendo.2022.1042060.
Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy.
Meloni A, Pistoia L, Ricchi P, Allo M, Rosso R, Cuccia L
Blood Adv. 2022; 7(10):2237-2240.
PMID: 36332057
PMC: 10196914.
DOI: 10.1182/bloodadvances.2022008805.
Emerging Roles of the Iron Chelators in Inflammation.
Di Paola A, Tortora C, Argenziano M, Marrapodi M, Rossi F
Int J Mol Sci. 2022; 23(14).
PMID: 35887336
PMC: 9318075.
DOI: 10.3390/ijms23147977.
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload.
Origa R, Cinus M, Pilia M, Gianesin B, Zappu A, Orecchia V
J Clin Med. 2022; 11(7).
PMID: 35407617
PMC: 8999930.
DOI: 10.3390/jcm11072010.
Therapeutic potential of silymarin as a natural iron-chelating agent in β-thalassemia intermedia.
Reisi N, Esmaeil N, Gharagozloo M, Moayedi B
Clin Case Rep. 2022; 10(1):e05293.
PMID: 35106163
PMC: 8784915.
DOI: 10.1002/ccr3.5293.
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto V, Forni G
Int J Mol Sci. 2020; 21(22).
PMID: 33233561
PMC: 7699680.
DOI: 10.3390/ijms21228771.